Tilray Brands, Inc. Common Stock
TLRYTilray Brands, Inc. is a global leader in the production and distribution of medical cannabis, adult-use cannabis, and wellness products. Founded in 2013, the company operates through various subsidiaries and brands, offering a range of cannabis products, including cannabis flowers, oils, and edibles, to both medical and recreational markets worldwide. Tilray emphasizes research, quality, and innovation within the rapidly evolving cannabis industry.
Company News
BrewDog and Tilray Brands are launching a £1 million bar tab promotion at participating BrewDog pubs across England, Scotland, and Ireland from July 20 through September 30, 2026. The promotion offers fans two free pints per person via the BrewDog Treats loyalty platform, available on a first-come, first-served basis. The initiative aims to brin...
President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilra...
Breckenridge Distillery, a subsidiary of Tilray Brands, announced the launch of Breck Vodka Seltzer, a new ready-to-drink product line available in four flavors (lime, grapefruit, peach, and tropical) at 5% ABV. The product is currently available in Colorado retailers with national expansion planned for Fall 2026, priced at $11-13.99 for 4-packs ...
On July 15, the DEA will conclude its hearing on rescheduling cannabis from Schedule I to Schedule III. While Tilray doesn't directly operate U.S. cannabis businesses and won't immediately benefit from tax relief, the company is well-positioned for long-term cannabis reform with its diversified international medical cannabis business, craft bever...
Tilray Brands has lost over 90% of its value in five years and remains unprofitable despite diversifying into craft brewing, hemp wellness, and pharmaceuticals. While recent U.S. cannabis reclassification to Schedule III could create medical research opportunities, the company faces significant headwinds including weak financial results, stringen...
